Free shipping on all orders over $ 500

MI-3454

Cat. No. M13373

All AbMole products are for research use only, cannot be used for human consumption.

MI-3454  Structure
Size Price Availability Quantity
5mg USD 620  USD620 In stock
10mg USD 980  USD980 In stock
25mg USD 1950  USD1950 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MI-3454 is a highly potent and selective inhibitor of Menin-MLL1 interaction with an IC50 of 0.51 nM.

Chemical Information
Molecular Weight 636.73
Formula C32H35F3N8OS
CAS Number 2134169-43-8
Solubility (25°C) DMSO:31.25 mg/mL
Storage 4°C, dry, sealed
References

[1] Hongzhi Miao, et al. Blood. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations

[2] Szymon Klossowski, et al. J Clin Invest. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia

Related Epigenetic Reader Domain Products
dBRD9 dihydrochloride 

dBRD9 dihydrochloride is a selective BRD9 PROTAC degrader.

BBC0403 

BBC0403 is a selective BRD2 inhibitor with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively.

BAY-155 

BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM.

FHT-1015 

FHT-1015 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with IC50s of ≤10 nM.

ISOX-DUAL 

ISOX-DUAL is a dual CBP/BRD4 inhibitor with IC50 values of 0.65 μM and 1.5 μM for CBP and BRD4, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: MI-3454 supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.